Zhang, Zefan http://orcid.org/0009-0004-3691-3642
Xue, Pei
Bendlin, Barbara B. http://orcid.org/0000-0002-0580-9875
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
De Felice, Fernanda http://orcid.org/0000-0001-8358-0589
Tan, Xiao
Benedict, Christian http://orcid.org/0000-0002-8911-4068
Article History
Received: 28 February 2024
Revised: 31 July 2024
Accepted: 1 August 2024
First Online: 11 August 2024
Competing interests
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). BBB has served at scientific advisory boards and/or as a consultant for New Amsterdam, Cognito Therapeutics, and Merry Life and has received amyloid and tau PET tracers and precursors from AVID radiopharmaceuticals. The other authors declare there are no competing financial interests related to the content of this article.